TG Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TGTX, updated each market day.
TGTX AI Sentiment
AI sees no strong directional signal for TG Therapeutics, Inc. stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Sector
Exchange
Market Cap
$8,643,809,422
Cap Tier
Employees
399
Headquarters
NEW YORK, NY
Listed Since
Dec. 14, 1995
Website
TGTX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TGTX Volatility
TG Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
